Invivyd (IVVD) vs SAB Biotherapeutics (SABS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed Invivyd (IVVD) over the past year, gaining 23.1% versus a loss of 55.3%. Over five years, SABS leads with a -97.1% price change compared with -97.8% for IVVD. SAB Biotherapeutics is the larger company by market cap ($257.5 million vs $200.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | SABS |
|---|---|---|
| Share price | $0.6816 | $2.83 |
| Market cap | $200.91M | $257.49M |
| 1-day change | -6.45% | -1.74% |
| YTD return | -70.50% | -22.99% |
| 1-year return | -55.30% | +23.08% |
| 5-year return | -97.75% | -97.15% |
| EPS (TTM) | $-0.33 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $5.15 |
| 52-week low | $0.528 | $2.10 |
| Distance from 52-week high | -77.80% | -45.05% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1367.14% | +311.31% |
| Average volume | 4.78M | 489.83K |
| Shares outstanding | 294.76M | 90.99M |
| Employees | 122 | 86 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed IVVD by 78.4 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 86 employees
IVVD vs SABS FAQ
Which is bigger, Invivyd or SAB Biotherapeutics?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $257.49M compared with $200.91M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or SABS?
SABS returned +23.08% over the past 12 months, compared with -55.30% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and SAB Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.